Company Deep Dive
Read the full research report: business segments breakdown, earnings transcripts review, management credibility analysis, competitive landscape, and scenarios.
SNY
Strong BuyFull HouseAPPROVESanofi · Healthcare · France · $107.4B · Avg Vol: $113M/d
Passes the eligibility threshold with all three legs (Quality 66, Value 76, Momentum 61) above 60. No adverse in-house signals or negative EPS revisions were identified, supporting a screen-pass.
COMPANY DESCRIPTION
Sanofi is a global biopharmaceutical company engaged in the research, development, manufacturing, and marketing of a broad range of healthcare solutions, encompassing prescription drugs, vaccines, and consumer healthcare products. Its significant competitive moat stems from a highly diversified portfolio of patented drugs and vaccines, strong global R&D capabilities, and extensive commercial reach across multiple therapeutic areas. Sanofi is a leading multinational pharmaceutical firm, particularly prominent in vaccine production and innovation in rare diseases and immunology.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 47.2B | 48.4B | 51.5B | 54.3B | 4.8% | 56.9B | 59.4B | 63.2B | 7.9% |
| EPS | 3.12 | 2.51 | 2.67 | 3.72 | 6.0% | 1.88 | 4.00 | 4.32 | 7.7% |
| Shares | 1.3B | 1.3B | 1.3B | 1.2B | -4.2% | — | — | — | — |
| Debt | 24.7B | 21.4B | 20.8B | 23.6B | -1.4% | 27.4B | — | — | — |
| Equity | 87.0B | 86.1B | 90.1B | 83.0B | -1.5% | — | — | — | — |
| Op CF | 12.2B | 11.9B | 10.6B | 12.5B | 0.7% | 13.8B | — | — | — |
| Inv CF | -2.4B | -7.2B | -5.1B | -2.8B | — | — | — | — | — |
| Fin CF | -6.8B | -9.4B | -6.7B | -9.5B | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of SNY are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| SNY | Sanofi(you) | $107.4B | 95 | Strong Buy |
| G1SK34.SA | GSK plc | $101.2B | 92 | Strong Buy |
| BMY | Bristol-Myers Squibb Company | $136.0B | 98 | Strong Buy |
| N1VO34.SA | Novo Nordisk A/S | $201.0B | 94 | Strong Buy |
| PFE | Pfizer Inc. | $159.4B | 88 | Strong Buy |
| 4578.T | Otsuka Holdings Co., Ltd. | $40.0B | 96 | Strong Buy |
| AMGN | Amgen Inc. | $233.8B | 86 | Strong Buy |
| BAYN.DE | Bayer Aktiengesellschaft | $55.4B | 81 | Strong Buy |
| GILD | Gilead Sciences, Inc. | $180.6B | 75 | Buy |
| 4503.T | Astellas Pharma Inc. | $26.6B | 98 | Strong Buy |
Peer medians: ROE 2.7% · P/E 24.4x · Gross margin 52.5%